RECRUITING

A Study of TAK-360 in Adults With Idiopathic Hypersomnia

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. They may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feeling tired, even after taking daytime naps. Because of this sleepiness, they may have trouble focusing, thinking clearly, or keeping up with daily activities. They may also have symptoms like dizziness or feeling lightheaded. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that act like orexin may keep people awake. The main aim of this study is to learn how safe TAK-360 is and how well adults with IH tolerate it. Researchers also want to find out if TAK-360 can help people with IH stay awake and how much TAK-360 is needed to do that. Participants will be randomly (by chance, like drawing names from a hat) chosen to receive either TAK-360 or a placebo. The placebo looks just like TAK-360 but does not have any medicine in it. Using a placebo helps researchers learn about the real effect of the treatment.

Official Title

A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants With Idiopathic Hypersomnia (IH)

Quick Facts

Study Start:2025-02-07
Study Completion:2026-02-19
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06812078

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 70 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. The participant weighs greater than or equal to (≥) 40 kilograms (kg) and has a body mass index (BMI) between 16 and 38 kilograms per meter square (kg/m\^2) \[inclusive\].
  2. 2. The participant has a documented, current diagnosis of IH.
  1. 1. The participant has a current medical disorder associated with excessive daytime sleepiness (EDS) \[other than IH\].
  2. 2. The participant has medically significant thyroid disease.
  3. 3. The participant has a history of cancer in the past 5 years. (This exclusion does not apply to participants with carcinoma in situ \[such as basal cell carcinoma\] that has been treated and is stable, or who have been stable without further treatment. These participants may be included after approval by the medical monitor.)
  4. 4. The participant has any of the following viral infections based on a positive test result: Hepatitis B surface antigen (at screening), hepatitis C virus antibody (at screening), human immunodeficiency virus (HIV) antibody/antigen (at screening).
  5. 5. The participant has a clinically significant history of head injury or head trauma.
  6. 6. The participant has history of epilepsy, seizure, or convulsion (exception for a single febrile seizure in childhood).
  7. 7. The participant has a history of cerebral ischemia, transient ischemic attack (less than \[\<\]5 years from screening), intracranial aneurysm, or arteriovenous malformation.

Contacts and Locations

Study Contact

Takeda Contact
CONTACT
+1-877-825-3327
medinfoUS@takeda.com

Principal Investigator

Study Director
STUDY_DIRECTOR
Takeda

Study Locations (Sites)

Takeda Site 11
Redwood City, California, 94063
United States
Takeda Site 10
Santa Ana, California, 92705
United States
Takeda Site 19
Brandon, Florida, 33511
United States
Takeda Site 14
Winter Park, Florida, 32789
United States
Takeda Site 16
Denver, North Carolina, 28037
United States
Takeda Site 15
Huntersville, North Carolina, 28078-5082
United States
Takeda Site 12
Cincinnati, Ohio, 45245
United States
Takeda Site 17
Cincinnati, Ohio, 45245
United States
Takeda Site 13
Columbia, South Carolina, 29201
United States
Takeda Site 18
San Antonio, Texas, 78229
United States

Collaborators and Investigators

Sponsor: Takeda

  • Study Director, STUDY_DIRECTOR, Takeda

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02-07
Study Completion Date2026-02-19

Study Record Updates

Study Start Date2025-02-07
Study Completion Date2026-02-19

Terms related to this study

Keywords Provided by Researchers

  • Idiopathic Hypersomnia
  • TAK-360

Additional Relevant MeSH Terms

  • Idiopathic Hypersomnia